Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gz-389988. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 known ✓ | P04629 | 19/20 | 0.98 |
| ▸ | CSF1R | P07333 | 20/20 | 0.98 |
| ▸ | NTRK2 | Q16620 | 19/20 | 0.98 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gz-389988 SCHEMBL31167982 | 1.00 | CSF1R (0.98) | CSF1RNTRK1NTRK2NTRK3 | |
| Gz-389988 SCHEMBL30387411 | 1.00 | CSF1R (0.98) | CSF1RNTRK1NTRK2NTRK3 | |
| Gz-389988 SCHEMBL16762937 | 0.99 | CSF1R (1.00) | CSF1RNTRK1NTRK2NTRK3 | |
| Gz-389988 SCHEMBL29589607 | 0.99 | CSF1R (1.00) | CSF1RNTRK1NTRK2NTRK3 | |
| Gz-389988 SCHEMBL29774374 | 0.99 | CSF1R (1.00) | CSF1RNTRK1NTRK2NTRK3 | |
| SCHEMBL16763058 | 0.91 | NTRK1 (1.00) | CSF1RNTRK1NTRK2NTRK3 | |
| SCHEMBL29774452 | 0.91 | NTRK1 (1.00) | CSF1RNTRK1NTRK2NTRK3 | |
| SCHEMBL16884597 | 0.90 | CSF1R (0.82) | CSF1RNTRK1NTRK2NTRK3 | |
| SCHEMBL16762920 | 0.89 | NTRK1 (1.00) | CSF1RNTRK1NTRK2NTRK3 | |
| SCHEMBL16762913 | 0.89 | NTRK1 (1.00) | CSF1RNTRK1NTRK2NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023086564-A1 | CRYSTALLINE IMIDAZO[4,5-B]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | GENZYME CORPORATION (US) | 2023-05-19 | — | — | WO | claimed |
| EP-4713325-A1 | PARTICLES OF IMIDAZO [4,5-B] PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | Centrexion Therapeutics Corporation (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250250274-A1 | CRYSTALLINE IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | GENZYME CORPORATION | 2025-08-07 | — | — | US | disclosed |
| US-12291528-B2 | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions | GENZYME CORPORATION (US) | 2025-05-06 | — | — | US | disclosed |
| US-20240383892-A1 | PARTICLES OF IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-11-21 | — | — | US | disclosed |
| WO-2024238957-A1 | PARTICLES OF IMIDAZO [4,5-b] PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | CENTREXION THERAPEUTICS CORPORATION (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-4430043-A1 | CRYSTALLINE IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | Genzyme Corporation (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20240150352-A1 | CRYSTALLINE IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | GENZYME CORPORATION | 2024-05-09 | — | — | US | disclosed |
| US-11814383-B2 | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions | GENZYME CORPORATION (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2023086564-A1 | CRYSTALLINE IMIDAZO[4,5-B]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | GENZYME CORPORATION (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230151008-A1 | CRYSTALLINE IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | GENZYME CORPORATION | 2023-05-18 | — | — | US | disclosed |
| EP-4180428-A1 | CRYSTALLINE IMIDAZO[4,5-B]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | Genzyme Corporation (US) | 2023-05-17 | — | — | EP | disclosed |
| EP-4180428-A1 | CRYSTALLINE IMIDAZO[4,5-B]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | Genzyme Corporation (US) | 2023-05-17 | — | — | EP | disclosed |
| EP-3233057-A2 | PHARMACEUTICAL FORMULATIONS OF TROPOMYOSIN RELATED KINASE (TRK) INHIBITORS | Genzyme Corporation (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016100677-A2 | PHARMACEUTICAL FORMULATIONS OF TROPOMYOSIN RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151008-A1 | CRYSTALLINE IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | MUSK, TPM4, TPM3 | NTRK1 83/4885CSF1R 945/4885NTRK2 133/4885 |
| US-20250250274-A1 | CRYSTALLINE IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | MUSK, TPM4, TPM3 | NTRK1 83/4885CSF1R 945/4885NTRK2 133/4885 |
| US-12291528-B2 | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions | MUSK, TPM4, TPM3 | NTRK1 83/4885CSF1R 945/4885NTRK2 133/4885 |
| US-20240383892-A1 | PARTICLES OF IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | TPM4, TPM3, MUSK | NTRK1 26/4885CSF1R 581/4885NTRK2 105/4885 |
| US-20240150352-A1 | CRYSTALLINE IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | MUSK, TPM4, TPM3 | NTRK1 83/4885CSF1R 945/4885NTRK2 133/4885 |
| US-11814383-B2 | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions | MUSK, TPM4, TPM3 | NTRK1 83/4885CSF1R 945/4885NTRK2 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.